April 16, 2018 10:56 AM EDTUpdated 11:09 AM
News Briefing

Genen­tech inks $359M deal with Kine­ta; Celldex bat­tered af­ter ADC flops in PhI­Ib

Amber Tong

→ Genen­tech is com­mit­ting up to $359 mil­lion to pur­sue a nov­el tar­get for chron­ic neu­ro­path­ic pain. Their part­ner in this ex­clu­sive op­tion and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Scott Got­tlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this coun­try’

No­var­tis pays $1B up­front for PTC's Phase 2 Hunt­ing­ton's drug

FDA de­fends in­creased use of guid­ance in new re­port to Con­gress

Sanofi ear­marks €1B for new in­sulin pro­duc­tion fac­to­ry in Bei­jing   

Apogee tar­gets Dupix­ent head-to-head next year as it out­lines broad pipeline plans

Agenus launch­es bi­o­log­ics man­u­fac­tur­ing busi­ness to gen­er­ate cash

A service from the Financial Times